Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has announced the closure of its trading window for the consideration of unaudited financial results for the first quarter ending June 30, 2026. The window will be closed from July 1, 2026, and will reopen 48 hours after the announcement of the financial results. During this period, all directors, designated employees, insiders, and their immediate relatives are prohibited from trading in the company's securities. The exact date of the board meeting to approve these results will be communicated separately.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has received approval from BSE and NSE for the listing of 1,98,67,549 equity shares. These shares were issued to qualified institutional buyers through a Qualified Institutional Placement (QIP). The approval signifies a crucial step in the process, allowing the shares to be traded on the stock exchanges once all regulatory confirmations, including credit to beneficiary accounts by depositories, are completed. This move is expected to enhance the company's capital base and liquidity.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) announced the closure of its Qualified Institutions Placement (QIP) issue on June 19, 2026. The Finance & Investment Committee approved the allocation of 19,867,549 Equity Shares to eligible qualified institutional buyers at a price of ₹755 per share. This price includes a premium and reflects a discount of ₹16.73 per share on the floor price, as permitted by SEBI regulations. The company also approved the placement document and confirmed the allocation notes to be sent to the buyers, along with refund intimations for unsuccessful bidders. The issue opened on June 16, 2026.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has announced an Extraordinary General Meeting (EGM) to be held on July 9, 2026, at 4:00 PM IST via Video Conferencing. The primary agenda is to consider and approve a preferential issue of 77,02,182 warrants, convertible into equity shares, to promoter entities including Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharath Ventures LLP. This move is subject to necessary regulatory approvals and will be conducted in accordance with SEBI regulations.

Krishna Institute of Medical Sciences Ltd will convene an Extraordinary General Meeting (EGM) on Thursday, July 9, 2026, at 4:00 PM via Video Conferencing. The meeting's primary agenda is to seek shareholder approval for a special resolution concerning the preferential issue of 77,02,182 fully convertible warrants. These warrants, each exchangeable for one fully paid-up equity share of ₹2, are proposed to be issued to promoter entities, specifically Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP. The issuance is contingent upon obtaining necessary regulatory and shareholder approvals.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) announced the approval of its Qualified Institutional Placement (QIP) by its Finance & Investment Committee. The committee approved the preliminary placement document and authorized the opening of the issue on June 16, 2026. The floor price for the issue has been fixed at ₹771.73 per equity share, calculated as per SEBI ICDR Regulations. A subsequent meeting on June 19, 2026, will consider and approve the final issue price, potentially including a discount of up to 5%. The trading window for designated persons has been closed from June 16, 2026, until 48 hours after the issue price determination.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has filed its audited standalone and consolidated financial statements for the financial year ended March 31, 2026. These statements, approved by the Board of Directors on May 15, 2026, provide a true and fair view of the company's financial position and performance, in accordance with Indian accounting principles. The detailed financial statements, including the balance sheet, profit and loss statement, cash flow statement, and statement of changes in equity, have been audited by S.R. Batliboi & Associates LLP. Key audit matters, such as the impairment assessment of investments in and loans to subsidiaries, were addressed during the audit. The financial statements are subject to adoption by shareholders at the upcoming Annual General Meeting and are available on the company's investor website.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) announced that its Board of Directors has approved the issuance of 77,02,182 warrants convertible into equity shares at ₹779 each, aggregating ₹599.99 crore. The warrants will be issued on a preferential basis to promoter and promoter group entities, including Dr. Abhinay Bollineni and Mr. Adwik Bollineni. The company also approved convening an Extra-Ordinary General Meeting (EGM) on July 9, 2026, to seek shareholder approval for this preferential allotment. The issuance is subject to shareholder and regulatory approvals.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) announced that its Board of Directors will meet on June 13, 2026, to consider a proposal for raising funds. The fundraising could be through various instruments like equity shares, warrants, or other eligible securities via preferential issue or private placement. The board will also consider convening an extraordinary general meeting to seek shareholder approval for the fund-raising plan. Additionally, the trading window for designated persons will be closed until 48 hours after the board meeting's outcome is disseminated.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) announced its Q4FY26 and FY26 results. Q4FY26 total revenue stood at ₹1,084 Cr, a growth of 35.3% YoY. EBITDA was ₹216 Cr, up 6.8% YoY, with an EBITDA margin of 19.9%. PAT was ₹33 Cr. FY26 total revenue was ₹3,931 Cr, up 28.2% YoY, with EBITDA of ₹828 Cr, up 1.6% YoY. FY26 PAT was ₹242 Cr. Consolidated EPS for FY26 was ₹6.03, a degrowth of 37.2% YoY.